Keyword: Washington University in St. Louis
The week’s biotech news included a mutation-targeting treatment for ALS and a malaria vaccine targeting a transmission protein.
Itaconate, a compound produced by inflammatory cells, relieved psoriasis-like symptoms in mice.
Instead of seeking the underlying cause of a group of symptoms, scientists started with a mutation and then tracked down people who have it.
The latest in biotech research includes a new way to grow human heart muscle and uncovering a genetic abnormality at the root of ALS and dementia.
Researchers at Washington University School of Medicine have found that targeting the APOE protein helps clear Alzheimer's plaques in mice.
Tau secretion was thought to be a byproduct of cell death, but new research shows it is an active process.
A Stanford team aimed at host cells to fight flaviviruses, while Harvard scientists examined the longevity of Zika vaccines.
Boosting the hedgehog signaling pathway stopped fat cells from growing in mice fed a high-fat diet.
Vir Biotech CEO Geroge Scangos has lined up infectious disease and immunology expert Skip Virgin from Washington University as its new R&D head.
This past week saw new discoveries in treating heart failure, targeting Zika and dengue with one drug and inhibiting a cancer-promoting enzyme.